Base de dados : MEDLINE
Pesquisa : H01.158.201.636.475.750 [Categoria DeCS]
Referências encontradas : 1389 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 139 ir para página                         

  1 / 1389 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386434
[Au] Autor:Watanabe K
[Ad] Endereço:Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences.
[Ti] Título:[From a Ph.D. Thesis: Understanding the Past, Predicting the Future].
[So] Source:Yakugaku Zasshi;138(2):211-219, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: Posey et al. have reported multiple molecular diagnoses in 4.5% of cases (101/2076) in which whole-exome sequencing was informative. Distinct disease phenotypes affect different organ systems, whereas overlapping disease phenotypes are more likely to be caused by two genes encoding proteins that interact within the same pathway. My research projects at the Niigata University of Pharmacy have investigated underlying mechanisms involved in human disease, including fatty acid metabolism, diabetic cardiomyopathy, atopic dermatitis, colitis, hepatitis, etc. Three students from abroad graduated this year from the Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences. These students reported on treatments for heart disease, non-alcoholic steatohepatitis and atopic dermatitis, as well as the underlying mechanisms involved in each. The titles of these reports are "Study of the role of cardiac 14-3-3η protein in cardiac inflammation and adverse cardiac remodeling during heart failure in mice", "Non-alcoholic steatohepatitis: onset of mechanisms under diabetic background and treatment strategies" and "The role of HMGB1 and its cascade signaling pathway in atopic dermatitis". It can be concluded from these three theses that oxidative stress and inflammation are among the principal mechanisms underlying these diseases.
[Mh] Termos MeSH primário: Dermatite Atópica
Proteína HMGB1
Insuficiência Cardíaca
Hepatopatia Gordurosa não Alcoólica
[Mh] Termos MeSH secundário: Proteínas 14-3-3
Proteínas Quinases Ativadas por AMP
Animais
Dermatite Atópica/genética
Complicações do Diabetes
Estresse do Retículo Endoplasmático
Insuficiência Cardíaca/genética
Seres Humanos
Camundongos
Hepatopatia Gordurosa não Alcoólica/etiologia
Hepatopatia Gordurosa não Alcoólica/terapia
Estresse Oxidativo
Patologia Molecular
Sequenciamento Completo do Exoma
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (14-3-3 Proteins); 0 (HMGB1 Protein); EC 2.7.11.31 (AMP-Activated Protein Kinases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00111


  2 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453956
[Au] Autor:Ta HT; Li Z; Hagemeyer CE; Cowin G; Zhang S; Palasubramaniam J; Alt K; Wang X; Peter K; Whittaker AK
[Ad] Endereço:Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia. Electronic address: h.ta@uq.edu.au.
[Ti] Título:Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast.
[So] Source:Biomaterials;134:31-42, 2017 Jul.
[Is] ISSN:1878-5905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Magnetic resonance imaging (MRI) is a powerful and indispensable tool in medical research, clinical diagnosis, and patient care due to its high spatial resolution and non-limited penetration depth. The simultaneous use of positive and negative MRI imaging that employs the same contrast agents will significantly improve detection accuracy. Here we report the development of functional multimodal iron oxide nanoparticles for targeted MRI of atherothrombosis using a combination of chemical and biological conjugation techniques. Monodisperse, water-soluble and biocompatible ultra-small magnetic dual contrast iron oxide nanoparticles (DCIONs) were generated using a high-temperature co-precipitation route and appeared to be efficient positive and negative dual contrast agents for magnetic resonance imaging. Using a unique chemo-enzymatic approach involving copper-free click chemistry and Staphylococcus aureus sortase A enzyme conjugation, DCIONs were functionalized with single-chain antibodies (scFv) directed against activated platelets for targeting purposes. The DCIONs were also labelled with fluorescent molecules to allow for optical imaging. The antigen binding activity of the scFv was retained and resulted in the successful targeting of contrast agents to thrombosis as demonstrated in a range of in vitro and in vivo experiments. T - and T -weighted MRI of thrombi was recorded and demonstrated the great potential of dual T /T contrast iron oxide particles in imaging of cardiovascular disease.
[Mh] Termos MeSH primário: Plaquetas/fisiologia
Meios de Contraste/química
Compostos Férricos/química
Imagem por Ressonância Magnética/métodos
Nanopartículas de Magnetita/química
Patologia Molecular/métodos
[Mh] Termos MeSH secundário: Animais
Células CHO
Cricetulus
Citometria de Fluxo
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Ferric Compounds); 0 (Magnetite Nanoparticles); 1K09F3G675 (ferric oxide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  3 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29224409
[Au] Autor:Glorikian H; Warburg RJ; Moore K; Malinowski J
[Ad] Endereço:a New Ventures , VA , USA.
[Ti] Título:Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
[So] Source:Expert Opin Ther Pat;28(2):123-128, 2018 Feb.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The development of molecular diagnostics is a complex endeavor, with multiple regulatory pathways to consider and numerous approaches to development and commercialization. Companion diagnostics, devices which are "essential for the safe and effective use of a corresponding drug or diagnostic product" (see U.S. Food & Drug Administration, In Vitro Diagnostics - Companion Diagnostics, U.S. Dept. of Health & Human Services(2016), available at https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm ) and complementary diagnostics, which are more broadly associated with a class of drug, are becoming increasingly important as integral components of the implementation of precision medicine. Areas covered: The following article will highlight the intellectual property ('IP') considerations pertinent to molecular diagnostics development with special emphasis on companion diagnostics. Expert opinion/commentary Summary: For all molecular diagnostics, intellectual property (IP) concerns are of paramount concern, whether the device will be marketed only in the United States or abroad. Taking steps to protect IP at each stage of product development is critical to optimize profitability of a diagnostic product. Also the legal framework around IP protection of diagnostic technologies has been changing over the previous few years and can be expected to continue to change in the foreseeable near future, thus, a comprehensive IP strategy should take into account the fact that changes in the law can be expected.
[Mh] Termos MeSH primário: Propriedade Intelectual
Técnicas de Diagnóstico Molecular
Patologia Molecular/legislação & jurisprudência
[Mh] Termos MeSH secundário: Seres Humanos
Patentes como Assunto
Medicina de Precisão/métodos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1409209


  4 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468604
[Au] Autor:Giry C; Roquebert B; Li-Pat-Yuen G; Gasque P; Jaffar-Bandjee MC
[Ad] Endereço:Centre National Arbovirus Associé, CHU de la Réunion-Site Nord, Saint-Denis, Réunion, France. claude.giry@chu-reunion.fr.
[Ti] Título:Simultaneous detection of chikungunya virus, dengue virus and human pathogenic Leptospira genomes using a multiplex TaqMan® assay.
[So] Source:BMC Microbiol;17(1):105, 2017 05 03.
[Is] ISSN:1471-2180
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In 2005-2006 a major epidemics of Chikungunya disease occurred in South-West Indian Ocean islands. In Reunion Island, the magnitude of Chikungunya infection related symptoms was high and with over 38% of serological prevalence in the population. This epidemics illustrated the potential threat of emerging arboviral diseases for inhabitants of Reunion Island and elsewhere since vectors are worldwide distributed. A sentinel surveillance network was set-up to detect emerging pathogens associated with fever over 38 °C and in the absence of known etiologic causes. Leptospirosis is caused by a pathogenic spirochete of the Leptospira genus and is an endemic and recurrent seasonal disease of great concern in Reunion Island. To accurately diagnose potentially infected patients and to advise Health authorities on the presence of emerging pathogens, a rapid diagnostic test was needed that could differentiate between these 3 pathogens. METHODS: A one-step multiplex real-time PCR assay was developed that can simultaneously detect RNA of Chikungunya and Dengue viruses and leptospiral DNA with good performance for a routine diagnostic use. RESULTS: Simplex protocols already published were used with key modifications to implement a triplex assay which was set-up with a small reaction volume to improve cost efficiency. CONCLUSIONS: This approach has enabled greater diagnostic capacity in our laboratory. We established a multiplex approach validated and valuable for cost savings, and with the concurrent detection of 3 pathogens of public health concern.
[Mh] Termos MeSH primário: Vírus Chikungunya/genética
Vírus da Dengue/genética
Leptospira/genética
Reação em Cadeia da Polimerase Multiplex/métodos
[Mh] Termos MeSH secundário: Febre de Chikungunya/diagnóstico
Febre de Chikungunya/virologia
Vírus Chikungunya/patogenicidade
DNA Bacteriano/genética
DNA Bacteriano/isolamento & purificação
Dengue/diagnóstico
Dengue/virologia
Vírus da Dengue/patogenicidade
Genoma Bacteriano
Genoma Viral
Seres Humanos
Leptospira/patogenicidade
Leptospirose/diagnóstico
Leptospirose/microbiologia
Patologia Molecular/métodos
RNA Viral/genética
RNA Viral/isolamento & purificação
Sensibilidade e Especificidade
Alinhamento de Sequência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA, Bacterial); 0 (RNA, Viral)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1186/s12866-017-1019-1


  5 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29080836
[Au] Autor:Chen J; Yang J; Zhao S; Ying H; Li G; Xu C
[Ad] Endereço:Department of Child Health, Xiamen Maternal and Child Health Hospital, Xiamen, Fujian, China; Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
[Ti] Título:Identification of a novel mutation in the FGFR3 gene in a Chinese family with Hypochondroplasia.
[So] Source:Gene;641:355-360, 2018 Jan 30.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hypochondroplasia (HCH; OMIM 146000) is a common autosomal dominant skeletal dysplasia characterized by disproportionate short stature, short extremities, relative macrocephaly, and lumbar lordosis. Because of its clinical and genetic heterogeneity, gene mutational analysis is particularly important in diagnosis and the phenotypes may be ameliorated if diagnosed early. MATERIALS AND METHODS: In this study, we examined a Chinese family with HCH, performed an inductive analysis of their clinical features and radiographic results, and applied targeted exome sequencing (TES) technology to perform a molecular diagnosis. RESULTS: The proband and his mother all presented disproportionate short stature, short, stubby extremities, unchanged interpedicular distances from L1-L5, and short iliac bones, with a 'fish mouth-shaped' sciatic notch. The mother received induced abortion recently because an ultrasound showed short femur length of her fetus at 24-week gestation. Eventually, a novel heterozygous mutation (c.1145G>A) in FGFR3 was identified by TES in the proband, his mother, and her fetus; this causes the substitution of glycine with aspartic acid in codon 382. CONCLUSIONS: In this study, we diagnosed a Chinese pedigree with HCH based on clinical data, radiographic features, and genetic testing results. Our results extend the genetic mutation spectrum of FGFR3 and demonstrate that TES is an effective method for the diagnosis of skeletal dysplasia in clinical practices.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Asiático/genética
Osso e Ossos/anormalidades
Nanismo/diagnóstico
Nanismo/genética
Deformidades Congênitas dos Membros/diagnóstico
Deformidades Congênitas dos Membros/genética
Lordose/diagnóstico
Lordose/genética
Mutação/genética
Receptor Tipo 3 de Fator de Crescimento de Fibroblastos/genética
[Mh] Termos MeSH secundário: Adulto
Ácido Aspártico/genética
Criança
Exoma/genética
Glicina/genética
Heterozigoto
Seres Humanos
Masculino
Patologia Molecular/métodos
Linhagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
30KYC7MIAI (Aspartic Acid); EC 2.7.10.1 (FGFR3 protein, human); EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3); TE7660XO1C (Glycine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171030
[St] Status:MEDLINE


  6 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29054233
[Au] Autor:Bayliss CD; Booth KL; Williams R; Dark JH; Gould KF
[Ad] Endereço:Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom. Electronic address: christopher.bayliss@nhs.net.
[Ti] Título:Managing a Mycotic Thoracoabdominal Aneurysm: The Importance of Molecular Diagnostics.
[So] Source:Ann Thorac Surg;104(5):e379-e381, 2017 Nov.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Pneumococcal mycotic aneurysms are rare and associated with significant mortality and morbidity. Early intravenous antibiotic therapy and surgical intervention is the mainstay of treatment. Pneumococci frequently autolyze in blood cultures, making microbiological diagnosis challenging. We present the case of a man in his mid 70s with multiple thoracoabdominal mycotic aneurysms. Surgery was performed to a threatening saccular aortic arch aneurysm. Samples were sent for microbiological analysis and all were culture negative. The samples were then referred for bacterial 16S ribosomal RNA sequencing, which revealed evidence of infection with Streptococcus pneumoniae.
[Mh] Termos MeSH primário: Aneurisma Infectado/cirurgia
Aneurisma da Aorta Torácica/diagnóstico
Aneurisma da Aorta Torácica/cirurgia
Implante de Prótese Vascular/métodos
RNA Bacteriano/análise
Streptococcus pneumoniae/isolamento & purificação
[Mh] Termos MeSH secundário: Idoso
Aneurisma Infectado/diagnóstico
Antibacterianos/uso terapêutico
Aneurisma da Aorta Abdominal/diagnóstico
Aneurisma da Aorta Abdominal/cirurgia
Seguimentos
Seres Humanos
Imagem Tridimensional
Masculino
Patologia Molecular
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Medição de Risco
Índice de Gravidade de Doença
Toracotomia/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (RNA, Bacterial)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171022
[St] Status:MEDLINE


  7 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28992761
[Au] Autor:Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
[Ad] Endereço:1 Department of Obstetrics and Gynecology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
[Ti] Título:KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
[So] Source:Tumour Biol;39(10):1010428317733984, 2017 Oct.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Epithelial ovarian neoplasms are a heterogeneous group of tumors, including various malignancies with distinct clinicopathologic and molecular features. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. Implementation of targeted therapeutic strategies requires access to highly specific and highly sensitive diagnostic tests for rapid determination of mutation status. One candidate for such test is fully integrated, real-time polymerase chain reaction-based Idylla™ system for quick and simple detection of KRAS mutations in formaldehyde fixed-paraffin embedded tumor samples. The primary aim of this study was to verify whether fully integrated real-time polymerase chain reaction-based Idylla system may be useful in determination of KRAS mutation status in patients with borderline ovarian tumors and low-grade ovarian carcinomas. The study included tissue specimens from 37 patients with histopathologically verified ovarian masses, operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz (Poland) between January 2009 and June 2012. Based on histopathological examination of surgical specimens, 30 lesions were classified as low-grade ovarian carcinomas and 7 as borderline ovarian tumors. Seven patients examined with Idylla KRAS Mutation Test tested positive for KRAS mutation. No statistically significant association was found between the incidence of KRAS mutations and histopathological type of ovarian tumors. Mean survival of the study subjects was 48.51 months (range 3-60 months). Presence of KRAS mutation did not exert a significant effect on the duration of survival in our series. Our findings suggest that Idylla KRAS Mutation Test may be a useful tool for rapid detection of KRAS mutations in ovarian tumor tissue.
[Mh] Termos MeSH primário: Análise Mutacional de DNA/métodos
Mutação
Neoplasias Epiteliais e Glandulares/genética
Neoplasias Ovarianas/genética
Proteínas Proto-Oncogênicas p21(ras)/genética
Reação em Cadeia da Polimerase em Tempo Real/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Meia-Idade
Neoplasias Epiteliais e Glandulares/patologia
Neoplasias Ovarianas/patologia
Patologia Molecular/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (KRAS protein, human); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317733984


  8 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28736821
[Au] Autor:Virtanen E; Laurila P; Hagström J; Nieminen P; Auvinen E
[Ad] Endereço:Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
[Ti] Título:Testing for high-risk HPV in cervical and tonsillar paraffin-embedded tissue using a cartridge-based assay.
[So] Source:APMIS;125(10):910-915, 2017 Oct.
[Is] ISSN:1600-0463
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:This study evaluates the suitability of Xpert HPV (Cepheid, Sunnyvale, CA, USA) test for cervical and tonsillar formalin-fixed paraffin-embedded (FFPE) tissue samples as compared to the tests currently used in diagnostics. Cervical biopsies and liquid cytology (LC) samples were collected from 48 women attending colposcopy. Biopsies were processed for histology and tested for hrHPV using Xpert HPV. LC samples were tested using Xpert and Hybrid Capture 2 (HC2; Qiagen, Hilden, Germany) tests. Also 29 archived tonsillar carcinoma samples were tested using Xpert, and the results were compared with histology and immunohistochemical p16INK4a (p16) staining. Among valid cervical LC samples 46.8% were hrHPV positive using Xpert test and 55.3% with HC2. The sensitivity of Xpert was 84.6% as compared to HC2, and overall test concordance was 91.5%. Test concordance between valid Xpert results from biopsies and LC samples was 84.6%. Among valid tonsillar samples 70.4% were hrHPV positive, and concordance of 96.3% was found between Xpert and p16 staining. To conclude, Xpert HPV test cartridge provides a convenient platform to test individual samples, including FFPE samples. Further studies are needed to establish whether test sensitivity is sufficient to reliably differentiate between hrHPV positive and hrHPV negative head and neck carcinomas.
[Mh] Termos MeSH primário: Colo do Útero/virologia
Tonsila Palatina/virologia
Papillomaviridae/classificação
Papillomaviridae/isolamento & purificação
Patologia Molecular/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Histocitoquímica/métodos
Seres Humanos
Imuno-Histoquímica/métodos
Meia-Idade
Papillomaviridae/genética
Sensibilidade e Especificidade
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170725
[St] Status:MEDLINE
[do] DOI:10.1111/apm.12727


  9 / 1389 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28609008
[Au] Autor:Berry AB
[Ad] Endereço:CellNetix Pathology and Laboratories LLC, Seattle, Washington.
[Ti] Título:Analytic inquiry: Validation and practical considerations.
[So] Source:Cancer;125(S6):465-469, 2017 Jun.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Molecular diagnostics and cytopathology ideally are complementary medical services. When used together, they provide optimal benefit to patient care with the least risk of complications. However, many cytopathology laboratories are reluctant to bring in molecular tests, in part due to inexperience with regard to molecular test validation. This article is a brief review of the basic principles of molecular test validation as it applies to cytopathology samples. Regulatory constraints, practical considerations, and issues that are particular to cytopathology samples are discussed, along with a brief review of issues that pertain specifically to next-generation sequencing. This review should serve as a general guide to validating molecular tests in the cytopathology laboratory. Cancer Cytopathol 2017;125(6 suppl):465-9. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Técnicas de Diagnóstico Molecular
Neoplasias/genética
Reprodutibilidade dos Testes
[Mh] Termos MeSH secundário: Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Neoplasias/metabolismo
Neoplasias/patologia
Patologia Clínica
Patologia Molecular
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170614
[St] Status:MEDLINE
[do] DOI:10.1002/cncy.21871


  10 / 1389 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28561325
[Au] Autor:Bader LI; Solberg SM; Kaada SH; Bolstad N; Warren DJ; Gavasso S; Gjesdal CG; Vedeler CA
[Ad] Endereço:The Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBiRD), Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.
[Ti] Título:Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.
[So] Source:Scand J Immunol;86(3):165-170, 2017 Sep.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Immunogenicity is a frequent cause of secondary non-response to tumour necrosis factor (TNF) inhibitors. Drug level measurement and detection of antidrug antibodies have been shown to be cost effective and clinically relevant, and a large number of assays are available for these purposes. It is, however, difficult to compare assays and translate results into clinical meaningful information due to different methodological approaches and a lack of assay standardization. We have analysed infliximab drug levels and antidrug antibodies in 107 patient samples using enzyme-linked immunoassays (ELISA), immunofluorometric assays (IFMA) and reporter-gene assays (RGA). The RGA gave the lowest results for drug levels, whereas the IFMA detected the highest number of antidrug antibody positive sera. Applying individualized therapeutic ranges to each assay resulted in agreement among all three assays in 74% of samples for drug levels and 98% of samples for antidrug antibodies. We found that TNF inhibitor monitoring assays measure on different scales and that the agreement between quantitative results is limited. However, interassay differences can partially be overcome by assay-individualized translations of quantities into categories, which also is necessary for a meaningful clinical application. Our data demonstrate that assays should not be used interchangeably and that direct comparison of quantitative drug levels obtained with different assays should be avoided.
[Mh] Termos MeSH primário: Anticorpos Anti-Idiotípicos/sangue
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Ensaio de Imunoadsorção Enzimática/métodos
Fluorimunoensaio/métodos
Infliximab/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/imunologia
Feminino
Genes Reporter/genética
Seres Humanos
Masculino
Meia-Idade
Patologia Molecular
Medicina de Precisão
Padrões de Referência
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Fator de Necrose Tumoral alfa/imunologia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Anti-Idiotypic); 0 (Antibodies, Monoclonal); 0 (Tumor Necrosis Factor-alpha); B72HH48FLU (Infliximab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12572



página 1 de 139 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde